Weekly nab-Paclitaxel in Metastatic Breast Cancer – Summary and Results of an Expert Panel Discussion

Dokumenttyp: Zeitschriftenaufsatz

Autor(en) des Beitrags: Jackisch, Christian; Lück, Hans-Joachim; Untch, Michael; Bischoff, Joachim; Müller, Volkmar; Schmidt, Marcus; Thill, Marc; Kiechle, Marion

Titel des Beitrags: Weekly nab-Paclitaxel in Metastatic Breast Cancer – Summary and Results of an Expert Panel Discussion

Abstract: Taxanes are regarded as the most effective single agents in the treatment of metastatic breast cancer (MBC). For conventional taxanes, crucial toxicities and impairments in clinical efficacy are related to solvents necessary because of the agents’ hydrophobicity. The mandatory premedication with corticosteroids causes additional side effects. Nab-paclitaxel is a solvent-free colloidal suspension of paclitaxel and human serum albumin that exploits the physiological transport properties of albumin. It is registered as monotherapy with a recommended dose of 260 mg/m² every 3 weeks for the treatment of patients with MBC, who have failed a first-line treatment of metastatic disease and for whom a standard anthracycline treatment is not indicated. Clinical evidence is available for the registered 3-weekly administration and for alternative weekly schedules in first and further lines of therapy of patients with MBC. During an advisory board meeting, a group of 8 German breast cancer experts reviewed the clinical data of nab-paclitaxel in MBC and discussed how nab-paclitaxel could be used in clinical practice on the basis of the current data.

Stichworte: First-line therapy; Metastatic breast cancer; Chemotherapy; Weekly; <i>nab</i>-Paclitaxel; Paclitaxel;
Docetaxel

Zeitschriftentitel: Breast Care

Jahr: 2012

Band: 7

Heft / Issue: 2

Seiten: 137--143

Volltext / DOI: http://doi.org/10.1159/000338273

Verlag / Institution: S. Karger GmbH

Verlagsort: Freiburg, Germany

Print-ISSN: 1661-3805

E-ISSN: 1661-3805

Hinweise: Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianzbzw. Nationallizenz frei zugänglich. This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.

Occurences:
- Kollektionen > Open Access Publikationen > 2012
- Kollektionen > Open Access Publikationen > Verlage > Karger

entries: